The facility will evaluate new processes to complement its current proprietary technologies – Meltrex, Xellex, NanoMorph and smartCrystals – that target the formulation of soluble complex pharmaceutical substances.
In addition to a new formulation development center, which opened earlier in 2008 at the company’s headquarters, the Soliqs expansion is part of Abbott’s global investment in facilities and resources to advance its pipeline.
Jorg Breitenbach, senior director of drug product development and head of Soliqs, said: “Nearly 40% of pharmaceutical compounds never reach the clinical study phase because they cannot be absorbed in the human body. The Soliqs expansion builds on Abbott’s expertise in drug delivery technology and addresses the rising demand for innovative, patient-focused formulations.”